in Heidelberg

The group is investigating the mechanisms and the disease-relevant consequences of DNA methylation in several areas. We are focusing on the charactreization of DNMT enzymes in various model systems, we are establishing methods for the identification and characterization of aberrant DNA methylation patterns in cancer and we are developing DNMT inhibitors as novel drugs for cancer therapy. These projects are being pursued in close cooperations with partners from academic research institutions, medical centers and pharmaceutical companies.


No puplications for this group yet.


Dr. Frank Lyko
Deutsches Krebsforschungszentrum (DKFZ)
Abteilung Epigenetik (A130)
Im Neuenheimer Feld 580
69120 Heidelberg, Germany

Phone: +49 6221 423800
Fax: +49 6221 423802